AGNM Acrongenomics Issues Update

Acrongenomics, Inc. (OTCBB:AGNM Stock News) are pleased to update the current status of their main project, its involvement with Molecular Vision Limited. The Company is in discussions with two major European medical device companies with the intention that these companies participate as strategic investors in Acrongenomics. If these discussions end with positive results, the synergies between Acrongenomics and Molecular Vision would increase, and Acrongenomics would be in a better position to assist Molecular Vision towards achieving its business plan for the next two years. As matters progress, Acrongenomics will provide further updates and announcements.

About AGNM Stock Profile Acrongenomics Inc.

Acrongenomics Inc. is a publicly traded company that focuses on investing in and commercializing novel technology platforms concerning the Life Sciences sector. Acrongenomics brings novel and realistic concepts to market by transforming scientific innovations into tangible, consumer-orientated applications. The company has its headquarters in London, England.

About Molecular Vision:

Molecular Vision is an Imperial College spin-out company that develops low-cost diagnostic devices for use in the doctor's surgery and in the home. Its proprietary devices combine microfluidic chips with organic-semiconductor light-sources and photodetectors to provide lab-quality diagnostic tests in a miniaturised, easy-to-use, disposable format.

Important Information About Forward-Looking Statements

All statements in this news release that are other than statements of historical facts are forward-looking statements. Forward-looking statements in this document include that we can reach agreement with strategic investors and if so, we would be able to assist Molecular Vision achieve its business plan. A number of factors may affect and cause those results to differ materially from those indicated. Such factors include our limited operating history; Molecular Vision’s need for significant capital to finance internal growth as well as strategic acquisitions; its ability to attract and retain key employees and strategic partners; its ability to achieve and maintain profitability; competition from other providers of similar products and services; the possible unacceptability of Molecular Vision’s products by health care authorities and/or practitioners; and other unanticipated future events and conditions. For further information concerning risks and uncertainties that may affect our future results, please review the disclosures contained in our latest filings with the SEC, including our most recent annual report on Form 10-KSB, and subsequent quarterly reports on Form 10-QSB. Other than as required by federal securities laws, we undertake no obligation to publicly update or revise any of our forward-looking statements, whether as a result of changed circumstances, new information, future events, or for any other reason occurring after the date of this news release.

Acrongenomics Inc.
Platon Tzouvalis, President , 011 30 697 724 3620
platon@acrongen.com

« Previous | All Messages | AGNM Message Board Home | Ignore Poster